Autres langues COMPASS Pathways plc

Actions

CMPS

US20451W1018

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 05/10/2026			Varia. 5j.	Varia. 1 janv.
11,60 ^USD	-2,52%		-12,32%	+68,12%

30/09	Compass Pathways plc annonce la nomination de Kelley Boucher au poste de directrice des ressources humaines, à compter du 30 septembre 2026	CI
17/09	Transcript : COMPASS Pathways plc Presents at Deutsche Bank 2026 Healthcare Summit, Sep-17-2026 11:00 AM

Autres langues

05/10	Compass Pathways Announces New Employee Inducement Grants under Nasdaq Listing Rule 5635(4)
05/10	Compass Pathways : Celebrates Opening of New U.S. Office in Jersey City, New Jersey
02/10	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/09	Compass Pathways Appoints Kelley Boucher as Chief People Officer
30/09	Compass Pathways plc Announces Appointment of Kelley Boucher as Chief People Officer, Effective September 30, 2026
16/09	Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
15/09	Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
14/09	Experts urge FDA to set clear safety and access standards for psychedelic drugs (September 14)
14/09	Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360
10/09	Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
10/09	Compass Pathways to Participate in Investor Conferences the Week of September 14th
09/09	Compass Pathways Reports New 52-Week Topline Open-Label Data From Phase 3 COMP005 Trial Demonstrating Additional Benefit From Another COMP360 Dose In Part C Extending Durability Out To 1 Year
09/09	Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
08/09	Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
07/09	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/09	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09	Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
01/09	Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
06/08	Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
06/08	Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
06/08	Compass Pathways plc and U.S. Department of Veterans Affairs Collaborate for Investigational Study of Psilocybin
05/08	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/08	Compass Pathways Shares Rise Amid Wider Q2 Loss, Higher Operating Expenses
05/08	COMPASS Pathways plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Earnings Flash (CMPS) Compass Pathways Posts Q2 Loss $1.88 a Share, vs. FactSet Est of $0.33 Loss